Navigation Links
For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro

Angiomax/Angiox Will Retain Decision Resources' Gold-Standard Status in 2017 for the Treatment of STEMI with Percutaneous Coronary Intervention, According to a New Report from Decision Resources

WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in the treatment of ST-elevation myocardial infarction (STEMI). Clinical data and the opinions of interviewed thought leaders indicate that The Medicines Company's Angiomax/Angiox has advantages in this attribute over Eli Lilly's ReoPro, the sales-leading agent in percutaneous coronary intervention (PCI) treatment of STEMI.

The new report entitled STEMI: Significant Opportunity Awaits Drugs That Can Reduce Mortality Rates also finds that an antiplatelet agent administered with stenting that is associated with lower rates of mortality and thrombocytopenia than ReoPro and less severe drug interactions would earn a substantial patient share in STEMI. According to surveyed U.S. and European cardiologists, this patient share would be 50 percent in the United States and 40 percent in Europe.

In 2008, Decision Resources' proprietary clinical gold standard for STEMI treated with PCI was Angiomax/Angiox. Based on available data and expert opinion, Angiomax/Angiox will retain gold-standard status for STEMI in 2017. While some therapies in development for the treatment of STEMI with PCI hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed physicians indicate are inferior when compared with Angiomax/Angiox.

"Interviewed physicians regard Angiomax/Angiox as being highly efficacious because it is associated with significantly lower mortality rates than the standard PCI adjunctive therapy of unfractionated heparin and a glycoprotein IIb/IIIa inhibitor," said Decision Resources Analyst Jeremy Goldman, M.D. "This mortality reduction is associated with lower rates of bleeding with Angiomax/Angiox."

About the Report

STEMI: Significant Opportunity Awaits Drugs That Can Reduce Mortality Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. An ESC statement on gender differences in medical care and survival after myocardial infarction
2. New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
3. New system devised to guide doctors treating patients with symptomatic myocardial bridging
4. Myocardial infarction: Mortality for women not higher than for men
5. Increased risk of myocardial infarction and diabetes in East Germany
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Heart regenerates after infarction -- first trials with mice
8. ST elevation infarction
9. Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
10. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
11. President Michael Del Chiaro Interviewed by for ecommerce Expertise
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Intellitec Solutions announced today that they have ... as Microsoft’s official group for end users of Dynamics SL ERP software, the ... experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to the ...
(Date:11/27/2015)... ... 27, 2015 , ... The moment you stop improving is ... fulfilling the needs of advisers and clients but going above and beyond to ... customer service. However, there's always room for improvement, which is why the entire ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College ... Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD ... colleges, as only one of twelve colleges and universities in the state of California ...
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term Support) into its ... 11 LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
(Date:11/26/2015)... 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in the ... Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new 247-page ... therapeutic drug monitoring market, including emerging tests, technologies, ...
Breaking Medicine Technology: